Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Nico GagelmannDanai DimaMaximilian MerzHamza HashmiNausheen AhmedNatalia TovarMarta GarroteFriedrich StölzelKristin RathjeLuise FischerPatrick BornLisa SchäferAnca-Maria AlbiciNatalie SchubShlomit Kfir-ErenfeldMiri AssayagNathalie AsherieGerald Georg WulfSoraya KharboutliFabian MüllerLeyla ShuneJames A DavisFaiz AnwarVladan VucinicUwe PlatzbeckerFrancis AyukNicolaus KrögerJack KhouriCarmelo GurnariJoseph P McGuirkPolina StepenskyAl-Ola AbdallahCarlos Fernández de LarreaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Outcomes of patients with RRMM after CAR-T are comparable between Europe and the United States. The MyCARe model may facilitate optimal timing of CAR-T cells in patient-specific subgroups.